These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 34914074)

  • 21. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy.
    Richard G; Princiotta MF; Bridon D; Martin WD; Steinberg GD; De Groot AS
    Expert Rev Vaccines; 2022 Feb; 21(2):173-184. PubMed ID: 34882038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Personalized Dendritic-cell-based Vaccines Targeting Cancer Neoantigens.
    Kamigaki T; Takimoto R; Okada S; Ibe H; Oguma E; Goto S
    Anticancer Res; 2024 Sep; 44(9):3713-3724. PubMed ID: 39197920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse.
    Charneau J; Suzuki T; Shimomura M; Fujinami N; Mishima Y; Hiranuka K; Watanabe N; Yamada T; Nakamura N; Nakatsura T
    Cancer Sci; 2022 Apr; 113(4):1113-1124. PubMed ID: 35122353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
    Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
    Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of neoantigens for individualized therapeutic cancer vaccines.
    Lang F; Schrörs B; Löwer M; Türeci Ö; Sahin U
    Nat Rev Drug Discov; 2022 Apr; 21(4):261-282. PubMed ID: 35105974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.
    Peterson M; Murphy SN; Lainson J; Zhang J; Shen L; Diehnelt CW; Johnston SA
    BMC Immunol; 2020 May; 21(1):25. PubMed ID: 32370785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical and clinical development of neoantigen vaccines.
    Li L; Goedegebuure SP; Gillanders WE
    Ann Oncol; 2017 Dec; 28(suppl_12):xii11-xii17. PubMed ID: 29253113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computational Prediction and Validation of Tumor-Associated Neoantigens.
    Roudko V; Greenbaum B; Bhardwaj N
    Front Immunol; 2020; 11():27. PubMed ID: 32117226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. pTuneos: prioritizing tumor neoantigens from next-generation sequencing data.
    Zhou C; Wei Z; Zhang Z; Zhang B; Zhu C; Chen K; Chuai G; Qu S; Xie L; Gao Y; Liu Q
    Genome Med; 2019 Oct; 11(1):67. PubMed ID: 31666118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines.
    Aguilar-Gurrieri C; Barajas A; Rovirosa C; Ortiz R; Urrea V; de la Iglesia N; Clotet B; Blanco J; Carrillo J
    Cancer Immunol Immunother; 2023 Jul; 72(7):2113-2125. PubMed ID: 36820900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoantigens in Hematologic Malignancies.
    Biernacki MA; Bleakley M
    Front Immunol; 2020; 11():121. PubMed ID: 32117272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
    Bai P; Li Y; Zhou Q; Xia J; Wei PC; Deng H; Wu M; Chan SK; Kappler JW; Zhou Y; Tran E; Marrack P; Yin L
    Oncoimmunology; 2021 Jan; 10(1):1868130. PubMed ID: 33537173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteogenomics offers a novel avenue in neoantigen identification for cancer immunotherapy.
    Ren Y; Yue Y; Li X; Weng S; Xu H; Liu L; Cheng Q; Luo P; Zhang T; Liu Z; Han X
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113147. PubMed ID: 39270345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation-Derived Neoantigens for Cancer Immunotherapy.
    Castle JC; Uduman M; Pabla S; Stein RB; Buell JS
    Front Immunol; 2019; 10():1856. PubMed ID: 31440245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.
    Brito Baleeiro R; Liu P; Chard Dunmall LS; Di Gioia C; Nagano A; Cutmore L; Wang J; Chelala C; Nyambura LW; Walden P; Lemoine N; Wang Y
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy.
    Sim MJW; Sun PD
    Front Immunol; 2022; 13():833017. PubMed ID: 35222422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations.
    Panya A; Thepmalee C; Sawasdee N; Saengmuang S; Luangwattananun P; Yenchitsomanus PT
    Biomed Pharmacother; 2023 Dec; 168():115827. PubMed ID: 37939617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.